Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 3:30 AM ET

Biotechnology

Company Overview of Intercell USA, Inc.

Company Overview

Intercell USA, Inc. is a biopharmaceutical company that focuses on furthering the science and product application of transcutaneous immunization (TCI) in the prevention and treatment of infectious and autoimmune diseases, cancer, and allergies. The company focuses on the delivery of vaccines and immunostimulants to the skin through transcutaneous immunization technology. Intercell USA, Inc. was formerly known as Iomai Corporation and changed its name to Intercell USA, Inc. in August 2008 as a result of its acquisition by Intercell Ag. The company was founded in 1997 and is based in Gaithersburg, Maryland. As of August 5, 2008, Intercell USA, Inc. operates as a subsidiary of Valneva SE.

20 Firstfield Road

Suite 250

Gaithersburg, MD 20878

United States

Founded in 1997

110 Employees

Phone:

301-556-4500

Fax:

301-556-4501

Key Executives for Intercell USA, Inc.

Chief Executive Officer and Director
Age: 60
President and Director
Age: 52
Co-Founder, Chief Scientific Officer and Senior Vice President
Age: 61
Chief Financial Officer and Secretary
Age: 46
Vice President of Operations
Age: 47
Compensation as of Fiscal Year 2015.

Intercell USA, Inc. Key Developments

Intercell USA, Inc. Announces U.S. Distribution and Marketing Services Agreements with VaxServe, Inc

Valneva SE announced that its fully owned US subsidiary Intercell USA, Inc. has entered into distribution and marketing services agreements with VaxServe, Inc. for Valneva's Japanese encephalitis (JE) vaccine IXIARO in the United States (U.S.). This collaboration is part of Valneva's strategy to commercialize IXIARO through a combination of its own sales & marketing infrastructure and distribution agreements with established local partners at favorable terms. Under the terms of the agreements, VaxServe will perform marketing and promotional services and distribute Valneva's Japanese encephalitis vaccine exclusively in the U.S. private market beginning December 18, 2015. Through the agreements, Valneva and VaxServe are working together to increase the private market for IXIARO vaccine in the U.S. he agreements do not include the distribution of the vaccine by VaxServe to the public market, including the U.S. military and other federal governmental agencies, which Valneva will handle directly.

Similar Private Companies By Industry

Company Name Region
TwoF, Inc. United States
Bridger Technologies, Inc. United States
EyeCyte, Inc. United States
Rodin Therapeutics Inc. United States
Impel Neuropharma Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intercell USA, Inc., please visit www.iomai.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.